First Quadrant’s Palvella Therapeutics PVLA Stock Holding History

First Quadrant’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-71	Closed	-$22K	–	540
2021 Q4	$22K	Buy	+71	New	+$22.7K	﹤0.01%	467
2019 Q4	–	Sell	-380	Closed	-$104K	–	623
2019 Q3	$104K	Sell	380 -341	-47%	-$132K	0.01%	482
2019 Q2	$271K	Sell	721 -378	-34%	-$113K	0.02%	480
2019 Q1	$294K	Sell	1,099 -866	-44%	-$206K	0.02%	440
2018 Q4	$418K	Hold	1,965	–	–	0.03%	391
2018 Q3	$880K	Sell	1,965 -1,135	-37%	-$493K	0.02%	400
2018 Q2	$1.26M	Sell	3,100 -30	-1%	-$14.3K	0.02%	381
2018 Q1	$1.71M	Buy	3,130 +2,020	+182%	+$1.25M	0.03%	337
2017 Q4	$670K	Buy	1,110 +84	+8%	+$39.1K	0.01%	498
2017 Q3	$473K	Buy	+1,026	New	+$438K	0.01%	561

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Quadrant's PVLA Position: Q1 2022 in Review

First Quadrant sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 71 shares — an estimated $22K sold.

First Quadrant first reported a position in PVLA in Q3 2017 and held it in 10 quarters. The position peaked at $1.71M in Q1 2018. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

First Quadrant reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 71 Palvella Therapeutics shares in Q1 2022, an estimated $22K.
First Quadrant first reported a position in Palvella Therapeutics in Q3 2017 and held it in 10 quarters.
First Quadrant's Palvella Therapeutics position peaked at $1.71M in Q1 2018.
71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.